Pulmonary Arterial Hypertension Market Research Report
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Pulmonary Arterial Hypertension Market, By Drug Class
7.1. Pulmonary Arterial Hypertension Market, by Drug Class, 2021-2030
7.1.1. Endothelin Receptor Antagonists (ERAs)
7.1.1.1. Market Revenue and Forecast (2019-2030)
7.1.2. PDE-5 Inhibitors
7.1.2.1. Market Revenue and Forecast (2019-2030)
7.1.3. Prostacyclin and Prostacyclin Analogs
7.1.3.1. Market Revenue and Forecast (2019-2030)
7.1.4. SGC Stimulators
7.1.4.1. Market Revenue and Forecast (2019-2030)
Chapter 8. Global Pulmonary Arterial Hypertension Market, By Type
8.1. Pulmonary Arterial Hypertension Market, by Type, 2021-2030
8.1.1. Branded
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Generics
8.1.2.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Pulmonary Arterial Hypertension Market, By Route of Administration
9.1. Pulmonary Arterial Hypertension Market, by Route of Administration, 2021-2030
9.1.1. Oral
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Intravenous/ subcutaneous
9.1.2.1. Market Revenue and Forecast (2019-2030)
9.1.3. Inhalational
9.1.3.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Pulmonary Arterial Hypertension Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.1.2. Market Revenue and Forecast, by Type (2019-2030)
10.1.3. Market Revenue and Forecast, by Route of Administration (2019-2030)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.1.4.2. Market Revenue and Forecast, by Type (2019-2030)
10.1.4.3. Market Revenue and Forecast, by Route of Administration (2019-2030)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.1.5.2. Market Revenue and Forecast, by Type (2019-2030)
10.1.5.3. Market Revenue and Forecast, by Route of Administration (2019-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.2.2. Market Revenue and Forecast, by Type (2019-2030)
10.2.3. Market Revenue and Forecast, by Route of Administration (2019-2030)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.2.4.2. Market Revenue and Forecast, by Type (2019-2030)
10.2.4.3. Market Revenue and Forecast, by Route of Administration (2019-2030)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.2.5.2. Market Revenue and Forecast, by Type (2019-2030)
10.2.5.3. Market Revenue and Forecast, by Route of Administration (2019-2030)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.2.6.2. Market Revenue and Forecast, by Type (2019-2030)
10.2.6.3. Market Revenue and Forecast, by Route of Administration (2019-2030)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.2.7.2. Market Revenue and Forecast, by Type (2019-2030)
10.2.7.3. Market Revenue and Forecast, by Route of Administration (2019-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.3.2. Market Revenue and Forecast, by Type (2019-2030)
10.3.3. Market Revenue and Forecast, by Route of Administration (2019-2030)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.3.4.2. Market Revenue and Forecast, by Type (2019-2030)
10.3.4.3. Market Revenue and Forecast, by Route of Administration (2019-2030)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.3.5.2. Market Revenue and Forecast, by Type (2019-2030)
10.3.5.3. Market Revenue and Forecast, by Route of Administration (2019-2030)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.3.6.2. Market Revenue and Forecast, by Type (2019-2030)
10.3.6.3. Market Revenue and Forecast, by Route of Administration (2019-2030)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.3.7.2. Market Revenue and Forecast, by Type (2019-2030)
10.3.7.3. Market Revenue and Forecast, by Route of Administration (2019-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.4.2. Market Revenue and Forecast, by Type (2019-2030)
10.4.3. Market Revenue and Forecast, by Route of Administration (2019-2030)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.4.4.2. Market Revenue and Forecast, by Type (2019-2030)
10.4.4.3. Market Revenue and Forecast, by Route of Administration (2019-2030)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.4.5.2. Market Revenue and Forecast, by Type (2019-2030)
10.4.5.3. Market Revenue and Forecast, by Route of Administration (2019-2030)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.4.6.2. Market Revenue and Forecast, by Type (2019-2030)
10.4.6.3. Market Revenue and Forecast, by Route of Administration (2019-2030)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.4.7.2. Market Revenue and Forecast, by Type (2019-2030)
10.4.7.3. Market Revenue and Forecast, by Route of Administration (2019-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.5.2. Market Revenue and Forecast, by Type (2019-2030)
10.5.3. Market Revenue and Forecast, by Route of Administration (2019-2030)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.5.4.2. Market Revenue and Forecast, by Type (2019-2030)
10.5.4.3. Market Revenue and Forecast, by Route of Administration (2019-2030)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Drug Class (2019-2030)
10.5.5.2. Market Revenue and Forecast, by Type (2019-2030)
10.5.5.3. Market Revenue and Forecast, by Route of Administration (2019-2030)
Chapter 11. Company Profiles
11.1. United Therapeutics Corporation
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Bayer
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Gilead Sciences, Inc.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Johnson & Johnson
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Viatris Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. GlaxoSmithKline
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Sandoz Inc. (Novartis)
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Lupin Pharmaceuticals, Inc.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Sun Pharmaceutical Industries, Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Teva Pharmaceutical Industries Ltd.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers